Journal article

Good Studies Evaluate the Disease While Great Studies Evaluate the Patient: Development and Application of a Desirability of Outcome Ranking Endpoint for Staphylococcus aureus Bloodstream Infection

Sarah B Doernberg, Tien Tram Tran Thuy, Steven YC Tong, Mical Paul, Dafna Yahav, Joshua S Davis, Leonard Leibovici, Helen W Boucher, G Ralph Corey, Sara E Cosgrove, Henry F Chambers, Vance G Fowler, Scott R Evans, Thomas L Holland

CLINICAL INFECTIOUS DISEASES | OXFORD UNIV PRESS INC | Published : 2019

Abstract

BACKGROUND: Desirability of outcome ranking (DOOR) is an innovative approach in clinical trials to evaluate the global benefits and risks of an intervention. We developed and validated a DOOR endpoint for Staphylococcus aureus bloodstream infection (BSI) through a survey to infectious diseases clinicians and secondary analysis of trial data. METHODS: We administered a survey of 20 cases of S. aureus BSI, asking respondents to rank outcomes by global desirability. Correlations and percentage of pairwise agreement among rankings were estimated to inform development of a DOOR endpoint, which was applied to 2 prior S. aureus BSI trials. The probability that a patient randomly assigned to experim..

View full abstract

University of Melbourne Researchers

Grants

Awarded by National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH)


Awarded by NIH


Awarded by Australia's National Health and Medical Research Council


Awarded by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES


Funding Acknowledgements

This study was supported in part by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH; award UM1AI104681). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. V. G. F. was supported by the NIH (K24-AI093969). J. S. D. and S. Y. T. received salary support from Australia's National Health and Medical Research Council (Career Development Fellowships 1083105 and 1145033, respectively).